Skip to main content

Table 1 Demographics and baseline characteristics

From: Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia

Characteristics No-PRS group (N = 315) PRS group (N = 59) Statistics Total (N = 374)
  Mean SD Mean SD F P Mean SD
Age 32.9 10.9 31.2 10.0 1.30 0.256 32.6 10.8
Education (years) 12.2 2.3 12.6 2.2 1.74 0.188 12.2 2.3
Age at onset 26.6 8.9 24.4 7.6 3.18 0.075 26.3 8.8
Duration of illness (years) 6.6 6.7 7.1 7.7 0.23 0.628 6.7 6.9
Risperidone dose at baseline (mg/d) 4.3 0.6 4.4 0.6 0.30 0.582 4.4 0.6
Total treatment in this episode (months) 5.3 5.1 5.2 4.3 0.04 0.850 5.3 5.0
Overall length of risperidone treatment in this episode (days) 83.5 54.1 90.2 59.7 0.74 0.389 84.5 55.0
Length of risperidone treatment at optimal therapeutic dose (days) 55.4 48.7 54.6 25.1 0.02 0.901 55.2 45.8
PANSS total score 39.1 9.5 42.8 10.0 7.66 0.006 39.5 9.6
  N % N % χ2 P N %
Number of male participants 166 52.7 6 10.2 36.185 <0.001 172 46.0
Married 133 42.2 27 45.8 0.440 0.802 160 42.8
Family history of psychiatric disorder(s) 25 7.9 8 13.6 1.953 0.162 33 8.8
Unemployed 149 47.9 30 50.2 1.450 0.484 179 47.8
  1. PANSS Positive and Negative Syndrome Scale, SD standard deviation